Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey

Lenzen, Mattie J.

doi:10.1016/j.ehj.2004.06.006

Cited by 325 publications

(258 citation statements)

References 37 publications

Supporting

Mentioning

213

Contrasting

Unclassified

Order By: Relevance

“…In the elderly population, factors associated with HFrEF were hospitalization and Boston scores ≥ 5, whereas in the population under 60 years of age, the factors were the significant presence of coronary artery disease and diabetes. These results are not consistent with those from other studies, showing that this population has its own characteristic progression of HFrEF [32][33][34][35] . The association of these risk factors in patients less than 60 years of age shows that such factors are involved in the early onset and in the genesis of heart dysfunction in this population.…”

Section: Discussioncontrasting

confidence: 57%

See 1 more Smart Citation

Insuficiência cardíaca com fração de ejeção preservada e com disfunção sistólica na comunidade

Moutinho¹,

Colucci²,

Alcoforado³

et al. 2008

Arq. Bras. Cardiol.

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 57%

“…The prevalence of arterial hypertension (three times that of CAD), observed especially among HF patients, was greater than that observed in developed countries 2,6,10,17,[31][32][33] . Arterial hypertension had a high prevalence in both forms of HF (HFrEF and HFpEF), with no differences between them.…”

Section: Discussionmentioning

confidence: 82%

Insuficiência cardíaca com fração de ejeção preservada e com disfunção sistólica na comunidade

Moutinho¹,

Colucci²,

Alcoforado³

et al. 2008

Arq. Bras. Cardiol.

View full text Add to dashboard Cite

show abstract

“…Compared to HF with reduced LVEF, HFPEF is more prevalent in women, black people, elderly, obese patients, patients with diabetes and patients with concomitant hypertension and/or left ventricular hypertrophy [1,2,4]. The severity of symptoms and the number of hospital admissions in patients with HFPEF versus those with reduced LVEF seem to be similar [5]. Even mortality rates, initially found to be lower compared to that of patients with reduced LVEF, appear now comparable in some studies [6][7][8][9].…”

Section: Background and Rationalementioning

confidence: 99%

Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study

et al. 2009

View full text Add to dashboard Cite

Background The SENIORS trial demonstrated that nebivolol has beneficial effects in patients with heart failure. However, the role of beta-blocker therapy in patients with heart failure and preserved left ventricular ejection fraction (HFPEF) is still unsettled. Objective To assess the long-term effects of administration of nebivolol, compared to placebo, on the clinical symptoms, exercise capacity and parameters of left ventricular (LV) function in patients with HFPEF. Methods The Effect of Long-term Administration of Nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with Diastolic Dysfunction (ELANDD) study is a prospective multicenter European trial in 120 patients with HFPEF randomised to nebivolol or placebo. HFPEF is defined as symptoms or signs of heart failure, a LV ejection fraction [45% and evidence of diastolic LV dysfunction by Doppler echocardiography. Procedures include a baseline clinical examination, 6-min walk test (6MWT), electrocardiography, Doppler echocardiography and Minnesota QoL questionnaire. Nebivolol or placebo is started at 2.5 mg/day and gradually uptitrated to 10 mg/day. After initiation of the study, patients are assessed at 1, 2, 5 and 6 weeks (titration phase) and at weeks 12 and 26. The primary endpoint is the change from baseline in the 6MWT distance with nebivolol versus placebo. Sample size calculations are based on an anticipated 15% difference (70 m) in the 6MWT distance between nebivolol and placebo-treated patients. This study will allow the collection of data regarding the possible For the ELANDD investigators.

show abstract

“…Recent studies, however, have shown that up to 30%-50% of patients admitted with acute HF may have preserved LVEF [14,15,[18][19][20][21]. Patients with preserved LVEF have a high rate of rehospitalisation and a similar, or only slightly lower, mortality, compared to patients with low LVEF [14,15].…”

Section: Systolic Versus Diastolic Left Ventricular Dysfunctionmentioning

confidence: 99%

“…Patients with a peak VO 2 b 14 ml/kg/min [8,10], and/or in NYHA class III to IV, with a LVEFb 25% may have an annual mortality rate of only 11-12% if euvolaemic and treated with beta-blockers and ACE inhibitors [12,13]. Indeed, patients with a normal LVEF and a recent HF hospitalisation may have a poorer prognosis [14,15]. More recently, an American expert group defined advanced HF as a "state in which patients have significant cardiac dysfunction with marked symptoms of dyspnoea, fatigue, or symptoms relating to end-organ hypoperfusion at rest or with minimal exertion despite maximal medical therapy" [16].…”

Section: Comparison With Previous Definitionsmentioning

confidence: 99%

Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology

Metra

Ponikowski²,

Dickstein

et al. 2007

European J of Heart Fail

346

240

View full text Add to dashboard Cite

Therapy has improved the survival of heart failure (HF) patients. However, many patients progress to advanced chronic HF (ACHF). We propose a practical clinical definition and describe the characteristics of this condition.Patients that are generally recognised as ACHF often exhibit the following characteristics: 1) severe symptoms (NYHA class III to IV); 2) episodes with clinical signs of fluid retention and/or peripheral hypoperfusion; 3) objective evidence of severe cardiac dysfunction, shown by at least one of the following: left ventricular ejection fraction b 30%, pseudonormal or restrictive mitral inflow pattern at Dopplerechocardiography; high left and/or right ventricular filling pressures; elevated B-type natriuretic peptides; 4) severe impairment of functional capacity demonstrated by either inability to exercise, a 6-minute walk test distance b 300 m or a peak oxygen uptake b 12-14 ml/kg/min; 5) history of N1 HF hospitalisation in the past 6 months; 6) presence of all the previous features despite optimal therapy. This definition identifies a group of patients with compromised quality of life, poor prognosis, and a high risk of clinical events. These patients deserve effective therapeutic options and should be potential targets for future clinical research initiatives.

show abstract

Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey

Abstract: In the EuroHeart Failure Survey, a high percentage of heart failure patients had PLVF. Although major clinical differences were seen between the groups, morbidity and mortality was high in both groups.

Cited by 325 publications

References 37 publications

Insuficiência cardíaca com fração de ejeção preservada e com disfunção sistólica na comunidade

Insuficiência cardíaca com fração de ejeção preservada e com disfunção sistólica na comunidade

Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study

Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology

Contact Info

Product

Resources

About